CDK9-IN-51
CDK9-IN-51 is a CDK9 inhibitor. CDK9-IN-51 binds stably to purified CDK9 protein via interactions with key active-site residues Cys106, Asp109, and Phe103. CDK9-IN-51 exhibits antiproliferative activity against multiple cancer cells. CDK9-IN-51 can be used for the research of cancer, such as lung carcinoma, cervical carcinoma and breast carcinoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2853500-43-1
- Fòrmula: C21H16FN3O
- Peso molecular:345.37
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
IC50 & Target
[1]|
CDK9 |
In Vitro
CDK9-IN-51 (Compound D3) binds stably to purified CDK9 protein via interactions with key active-site residues Cys106, Asp109, and Phe103, with a binding free energy of -85.33 kcal/mol and a docking score of -9.186 kcal/mol[1].
CDK9-IN-51 potently inhibits the proliferation of multiple cancer cell lines, including A549, SiHa, and MCF-7, with
IC50 values of 6.09, 3.33, and 9.74 μM,
respectively, and exhibits minimal toxicity to normal HEK-293t cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
No. CAS 2853500-43-1
-
Peso molecular 345.37
-
Fòrmula C21H16FN3O
-
SMILES
FC(C=C(C1=CC=NC=C1)C=C2)=C2NC(CC3=CNC4=CC=CC=C43)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CDK9-IN-51 Related Classifications
HY-183698 Related Classifications
Powered by Bioz